Abstract
Ingestion of arsenic-contaminated drinking water is associated with an increased risk of several cancers, including skin and bladder malignancies; but it is not yet clear whether such adverse effects are present at levels to which the U.S. population is exposed. In New Hampshire, detectable levels of arsenic have been reported in drinking water supplies throughout the state. Therefore, we have begun a population-based epidemiologic case-control study in which residents of New Hampshire diagnosed with primary squamous cell (n = 900) and basal cell (n = 1200) skin cancers are being selected from a special statewide skin cancer incidence survey; patients diagnosed with primary bladder cancers (n = 450) are being identified through the New Hampshire State Cancer Registry. Exposure histories of these patients will be compared to a control group of individuals randomly selected from population lists (n = 1200). Along with a detailed personal interview, arsenic and other trace elements are being measured in toenail clipping samples using instrumental neutron activation analysis. Household water samples are being tested on selected participants using a hydride generation technique with high-resolution inductively coupled plasma mass spectrometry. In the first 793 households tested arsenic concentrations ranged from undetectable (0.01 microgram/l) to 180 microgram/l. Over 10% of the private wells contained levels above 10 microgram/l and 2.5% were above 50 microgram/l. Based on our projected sample size, we expect at least 80% power to detect a 2-fold risk of basal cell or squamous cell skin cancer or bladder cancer among individuals with the highest 5% toenail concentrations of arsenic.
MeSH Terms
Adult
Aged
Arsenic/adverse effects,analysis
Carcinoma, Basal Cell/epidemiology,etiology
Carcinoma, Squamous Cell/epidemiology,etiology
Case-Control Studies
Environmental Exposure/analysis
Female
Humans
Male
Middle Aged
New Hampshire/epidemiology
Registries
Research Design
Risk Assessment
Sample Size
Skin Neoplasms/epidemiology,etiology
Urinary Bladder Neoplasms/epidemiology,etiology
Water Supply
Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Karagas M R
Department of Community and Family Medicine, Dartmouth Medical School, Dartmouth College, Hanover, New Hampshire, USA. margaret.karagas@dartmouth.edu
Tosteson T D
Blum J
Morris J S
Baron J A
Klaue B
References (13)
13 references, click to expand
-
Prevalence of skin cancer in an endemic area of chronic arsenicism in Taiwan.
J Natl Cancer Inst. 1968 Mar;40(3):453-63
PMID: 5644201
-
Correlations between carcinogenic trace metals in water supplies and cancer mortality.
Ann N Y Acad Sci. 1972 Jun 28;199:249-64
PMID: 4506509
-
Skin cancer and water arsenic in Lane County, Oregon.
Cancer. 1976 May;37(5):2523-32
PMID: 1260732
-
A dose-response analysis of skin cancer from inorganic arsenic in drinking water.
Risk Anal. 1989 Dec;9(4):519-28
PMID: 2608947
-
Arsenical cancer of skin. Histologic study with special reference to Bowen's disease.
Cancer. 1968 Feb;21(2):312-39
PMID: 4952508
-
Cancer risks from arsenic in drinking water.
Environ Health Perspect. 1992 Jul;97:259-67
PMID: 1396465
-
Serum beta-carotene level, arsenic methylation capability, and incidence of skin cancer.
Cancer Epidemiol Biomarkers Prev. 1997 Aug;6(8):589-96
PMID: 9264271
-
Case-control study of bladder cancer and arsenic in drinking water.
Am J Epidemiol. 1995 Mar 15;141(6):523-30
PMID: 7900719
-
High bladder cancer mortality in rural New England (United States): an etiologic study.
Cancer Causes Control. 1995 Jul;6(4):361-8
PMID: 7548724
-
Skin cancer.
Dermatol Clin. 1995 Jul;13(3):583-94
PMID: 7554506
-
Toenail samples as an indicator of drinking water arsenic exposure.
Cancer Epidemiol Biomarkers Prev. 1996 Oct;5(10):849-52
PMID: 8896897
-
Arsenic methylation capacity, body retention, and null genotypes of glutathione S-transferase M1 and T1 among current arsenic-exposed residents in Taiwan.
Mutat Res. 1997 Jun;386(3):197-207
PMID: 9219558
-
Toenail trace element levels as biomarkers: reproducibility over a 6-year period.
Cancer Epidemiol Biomarkers Prev. 1993 Sep-Oct;2(5):493-7
PMID: 8220096